Synonym
MD 770222; MD770222; MD-770222
IUPAC/Chemical Name
3-((4-(5-(Hydroxymethyl)-2-oxo-3-oxazolidinyl)phenoxy)methyl)benzonitrile
InChi Key
PICCEPOEDPVTBS-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H16N2O4/c19-9-13-2-1-3-14(8-13)12-23-16-6-4-15(5-7-16)20-10-17(11-21)24-18(20)22/h1-8,17,21H,10-12H2
SMILES Code
N#CC1=CC=CC(COC2=CC=C(N3C(OC(CO)C3)=O)C=C2)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
324.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rovei V, Chanoine F, Strolin Benedetti M, Zini R, Tillement JP. Plasma protein binding of the reversible type A MAO inhibitor cimoxatone (MD 780515). Biochem Pharmacol. 1983 Aug 1;32(15):2303-8. PubMed PMID: 6192825.
2: Strolin Benedetti M, Boucher T, Fowler CJ. The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):315-20. PubMed PMID: 6633672.
3: Strolin Benedetti M, Eschalier A, Lesage A, Dordain G, Rovei V, Zarifian E, Dostert P. Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man. Eur J Clin Pharmacol. 1984;26(1):71-7. PubMed PMID: 6538844.
4: Garrick NA, Seppala T, Linnoila M, Murphy DL. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone. Psychopharmacology (Berl). 1985;86(3):265-9. PubMed PMID: 2412251.
5: Rovei V, Rigal M, Sanjuan M, Thiola A. High-performance liquid chromatographic determination of cimoxatone and its O-demethyl metabolite in plasma. J Chromatogr. 1983 Oct 14;277:391-5. PubMed PMID: 6643627.
6: Poirier MF, Olié JP, Lôo H, Deniker P, Strolin Benedetti M, Rovei V, Lesage A. [Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor]. Encephale. 1983;9(4):331-43. French. PubMed PMID: 6368197.
